TheraGenetics Limited, a personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of central nervous system (CNS) disorders, announced today that Richard Kivel, Chief Executive Officer of TheraGenetics will present at the 2008 Boston Biotech R&D Conference, at 1:00 p.m. (ET) on October 22, 2008 at Harvard Medical School in Boston, Massachusetts. TheraGenetics' presentation will be moderated by Mike King of Rodman & Renshaw and will provide an overview of the company and its development efforts to bring personalized medicine diagnostics into clinical practice for patients living with diseases of the central nervous system, including schizophrenia, depression, bipolar disorder, Alzheimer's disease and ADHD (attention deficit hyperactivity disorder), through the use of pharmacogenetic tests.
"We are pleased to be presenting at the first ever Boston Biotech R&D conference," said Richard Kivel, Chief Executive Officer of TheraGenetics. "I look forward to sharing information with other leading companies and community leaders, as well as providing an update on the promising advances we are making with our R&D efforts to improve the treatment of patients with complex CNS disorders by predicting response and side-effects to drug treatments."
About The Boston Biotech R&D Conference
The 2008 Boston Biotech R&D Conference willtake place at Harvard Medical School and will highlightthe work of top academics as well asup-and-coming biotech companies in the Boston area. The agenda featureskeynotes fromseveral luminaries in medicine and research, including Jeffrey S. Flier, Dean of Harvard Medical School, Leonard Guarente, Ronald Kahn, Eric S. Lander,Robert Langer, Phillip Sharp, David Sinclair, as well asCEOsof the next generation of leading biotech and pharma companies from the Boston area. The conference is sponsored by Alexandria Real Estate Equities Inc., Pure Communications Inc., and Rodman & Renshaw, LLC. For more information, visit www.bostonbiotechconference.com.
About TheraGenetics
TheraGenetics is a privately held, personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of CNS disorders thereby bringing the right medicine to the right patient.
TheraGenetics was created in April 2006 as a spin-out of the Institute of Psychiatry at King's College London. Current investors include Swarraton Partners Ltd., Tudor Capital UK, IP Group PLC and Kinetique Biomedical Seed Fund. For more information please visit
www.theragenetics.com.
SOURCE: TheraGenetics Limited
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment